Back to Search
Start Over
Nanoparticle-mediated pulmonary drug delivery: state of the art towards efficient treatment of recalcitrant respiratory tract bacterial infections.
- Source :
-
Drug delivery and translational research [Drug Deliv Transl Res] 2021 Aug; Vol. 11 (4), pp. 1634-1654. Date of Electronic Publication: 2021 Mar 10. - Publication Year :
- 2021
-
Abstract
- Recalcitrant respiratory tract infections caused by bacteria have emerged as one of the greatest health challenges worldwide. Aerosolized antimicrobial therapy is becoming increasingly attractive to combat such infections, as it allows targeted delivery of high drug concentrations to the infected organ while limiting systemic exposure. However, successful aerosolized antimicrobial therapy is still challenged by the diverse biological barriers in infected lungs. Nanoparticle-mediated pulmonary drug delivery is gaining increasing attention as a means to overcome the biological barriers and accomplish site-specific drug delivery by controlling release of the loaded drug(s) at the target site. With the aim to summarize emerging efforts in combating respiratory tract infections by using nanoparticle-mediated pulmonary delivery strategies, this review provides a brief introduction to the bacterial infection-related pulmonary diseases and the biological barriers for effective treatment of recalcitrant respiratory tract infections. This is followed by a summary of recent advances in design of inhalable nanoparticle-based drug delivery systems that overcome the biological barriers and increase drug bioavailability. Finally, challenges for the translation from exploratory laboratory research to clinical application are also discussed and potential solutions proposed.
Details
- Language :
- English
- ISSN :
- 2190-3948
- Volume :
- 11
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Drug delivery and translational research
- Publication Type :
- Academic Journal
- Accession number :
- 33694082
- Full Text :
- https://doi.org/10.1007/s13346-021-00954-1